机构:
Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, Pittsburgh, PA 15240 USAUniv Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, Pittsburgh, PA 15240 USA
Roodman, G. David
[1
]
机构:
[1] Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, Pittsburgh, PA 15240 USA
Multiple myeloma (mm) is the most common cancer to involve bone with Up to 90% of patients developing bone lesions. The bone lesions are purely osteolytic in nature and do not heal in the vast majority of patients. Up to 60% of patients develop pathologic fractures over the course of their disease. Bone disease is a hallmark of MM, and myeloma bone disease differs front hone metastasis caused by other tumors. Although myeloma and other osteolytic metastases induce increased osteoclastic bone destruction, in contrast to other tumors, once myeloma tumor exceeds 50% in it local area, osteoblast activity is either severely depressed of absent. The basis For this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been the topic of intensive investigation over the last several years. These studies have helped to identify novel targets for treating myeloma bone disease and Will he discussed in this chapter. J. Cell. Biochem. 109: 283-29 1, 2010. (C) 2009 Wiley-Liss, Inc.